Table 6 Characteristics of patients according to the expression level of TMEM173
From: Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Characteristics | High expression (n = 63) | Low expression (n = 30) | P-value |
|---|---|---|---|
Age, years | 55.1 ± 1.7 | 51.9 ± 2.5 | 0.70 |
Male sex | 31 (49%) | 13 (43%) | 0.59 |
Pre-bevacizumab KPS score | 57.8 ± 1.9 | 60.0 ± 2.9 | 0.49 |
Molecular type | |||
 IDH wild type | 23 (37%) | 24 (80%) | 0.0001 |
 MGMT promoter status (methylated/unmethylated/NA) | 16/13/34 | 17/6/7 |  |
Surgical resection type | |||
 Partial resection | 21 (33%) | 17 (57%) | 0.03 |
 Gross total resection | 42 (67%) | 13 (43%) |  |
Drug treatment | |||
 Temozolomide + bevacizumab | 54 (86%) | 20 (67%) |  |
 Monotherapy | 9 (14%) | 10 (33%) |  |
 Temozolomide duration, days | 241.7 ± 26.0 | 203.8 ± 30.0 | 0.16 |
 Avastin dose, mg/kg | 591.2 ± 15.8 | 591.0 ± 22.6 | 0.96 |
Treatment outcomes | |||
 Overall survival, days | 981.3 ± 100.9 | 599.7 ± 50.6 |  < 0.001 |
 Progression-free survival, days | 525.6 ± 72.4 | 274.7 ± 36.6 |  < 0.001 |
 Initial tumor size, mm3 | 40219 ± 4196 | 43899 ± 7890 | 0.079 |
 Recurred tumor size, mm3 | 35148 ± 4903 | 22780 ± 6381 | 0.54 |